NEW YORK (Reuters Health) - The results of a study of healthy volunteers indicate that inhaled insulin has a faster onset of action than does subcutaneously injected insulin lispro or regular human insulin, German researchers report in the May issue of Diabetes Care.
Given these findings, senior investigator Dr. Tim Heise told Reuters Health that inhaled insulin “should be very well suited to cover prandial insulin needs.”
Dr. Heise of the Profil Institut fur Stoffwechselforschung GmbH, Neuss and colleagues note that although inhaled insulin appears to have desirable qualities, it has not been directly compared with fast-acting insulin lispro or regular insulin.
The researchers therefore conducted an open-label, three-way crossover study with 17 healthy volunteers who were randomized to 6 mg of inhaled insulin, 18 units of lispro or 18 units of regular insulin. “Glucose infusion rates and serum insulin concentrations were monitored over 10 hours,” the investigators report.
As noted, inhaled insulin had a significantly faster onset of action than the other agents. The time to maximal effect was similar to that of insulin lispro but was shorter than regular insulin.
These findings suggest that the “intensification of basal insulin supplementation -- required to improve glycemic control with short-acting insulin analogues -- may not be necessary with inhaled insulin,” Dr. Heise said.
Source: Diabetes Care 2005;28:1077-1082. [ Google search on this article ]
Copyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
